speaker photo

John McCamant

Editor

Medical Technology Stock Letter

John McCamant joined the Medical Technology Stock Letter as associate editor in 1987 and was named editor of this leading investment newsletter in August 2000. He has spent 25 years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, Mr. McCamant uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, Bloomberg, and Marketwatch.

Speaker Schedule

Tuesday, May 12, 2020 - 4:10 pm to 4:50 pm EDT Biotech Investing Post-COVID-19 Pandemic Focus: BIOTECH

Join John McCamant of the Medical Technology Stock Letter, whose editors have more than 70 years of combined experience in biotech investing, as he discusses how post-pandemic biotech stocks are poised to become the premier growth sector for the next decade. Biotech investing is the perfect nexus of wealth, health, and technology. Biotech will be a major part of the solution to COVID-19 —as it has already demonstrated —with over 100 new trials starting recently for treatments, vaccines, and diagnostic tools.

MoneyShow

For questions please contact our Client Relations Team at 800-970-4355 or 941-955-0323.

Social Updates

Follow us on social media to stay in the loop as more great speakers are added to the schedule!